Twenty-five million Americans suffer from ulcers. An ulcer is a sore or hole in the lining of the stomach or duodenum (the first part of the small intestine). People of any age can get an ulcer and women are affected just as often as men.
Helicobacter pylori (H. pylori) is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that nine out of ten ulcers are caused by H. pylori. Medicines that reduce stomach acid may make you feel better, but your ulcer may come back. Here's the good news: Since most ulcers are caused by this bacterial infection, they can be cured with the right antibiotics.
A new evidence-based instrument to assess and classify peristomal skin lesions was launched at the 2010 Joint Conference of the Wound, Ostomy and Continence Nurses Society and World Council of Enterostomal Therapists. The instrument, known as the SACS Instrument, represents the first content-validated instrument to objectively assess and classify peristomal lesions by type and location in relation to an individual's stoma.
With the results of the clinical trial at Duke University Medical Center completed, and the pending publication of the results, TMI is pleased to announce the development of their new clinical imaging system.
Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.
Negative health effects linked to taking too much supplemental calcium are on the rise, according to a commentary appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).
Quality Partners of Rhode Island, the state's Medicare Quality Improvement Organization, has equipped Ocean State nursing homes working to reduce pressure ulcers with copies of the Pocket Guide to Pressure Ulcers, a new reference resource.
POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.
Kinetic Concepts, Inc. today announced the company will feature its expanded line of negative pressure technology platform products and services at the annual European Wound Management Association congress in Geneva, Switzerland. Highlighting the company's commitment to innovative therapies, the new product line will improve the portability and adoption of V.A.C. Therapy, while further specializing the clinical application of negative pressure.
CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.
There's currently no reliable tool to help prosthetic developers fit artificial limbs without ensuing discomfort or pain, or tell medical personnel when bed-ridden patients need to be moved to avoid bedsores and other problems.
ROXRO PHARMA, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPRIX™ (ketorolac tromethamine) Nasal Spray, for the short-term (up to 5 days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level.
SANUWAVE Health, Inc.,, an emerging medical technology company focused on regenerative medicine, today reported financial results for the three months ended March 31, 2010 and provided a business update.
Proton pump inhibitors, medications that suppress acid in the stomach, appear to be associated with fractures in postmenopausal women and bacterial infections in many patients, and higher doses do not appear any more beneficial for treating bleeding ulcers, according to a series of reports in the May 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Wellstar International Inc. has announced they have started their second Beta Test in a Long Term Care Facility.
Sucampo Pharmaceuticals, Inc. today presented results of a phase 2 clinical trial of cobiprostone, an investigational drug, for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). These data were presented at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, as part of the distinguished abstract plenary session.
AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.
"If Stephen Harper is serious about maternal health and child health [as suggested by his plans for the upcoming G8 and G20 summits], he needs to recognize that healthy mothers come from healthy communities," Maude Barlow and Meera Karunananthan of the Council of Canadians write in a Chronicle Herald opinion piece that examines the connections between the health of women and children and access to drinking water and sanitation.
Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.
With over ten million diabetics in the U.S. alone and approximately 150,000 amputations performed yearly, inventor and American board-certified prosthetist John E. Rooney developed a custom-made ankle-foot orthosis with the trade name Ulcer Healing Orthosis or UHO.
Kinetic Concepts, Inc. today introduced V.A.C.Via Therapy System, a next-generation negative pressure wound therapy solution that offers clinicians and patients a mobile healing technology with the proven benefits and outcomes of V.A.C. Therapy.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.